

**IN THE CLAIMS:**

1-41.(Cancelled)

42.(New) An isolated antigenic peptide comprising an amino acid sequence consisting of SEQ ID NO: 4 that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.

43.(New) An isolated antigenic fusion protein comprising an amino acid sequence consisting of SEQ ID NO: 4 and a heterologous carrier protein that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.

44.(New) A pharmaceutical composition for inducing an anti-IgE immune response that does not cause anaphylaxis comprising one or more antigenic peptides consisting of an amino acid sequence of amino acid residues of a CH3 domain of an IgE molecule or a fragment thereof.

45.(New) The pharmaceutical composition of claim 44, wherein at least one antigenic peptide consists of the amino acid sequence of SEQ ID NO: 4.

46.(New) A pharmaceutical composition for inducing an anti-IgE immune response that does not cause anaphylaxis comprising one or more antigenic fusion proteins consisting of an amino acid sequence of amino acid residues of a CH3 domain of an IgE molecule or a fragment thereof; and a heterologous carrier protein.

47.(New) The pharmaceutical composition of claim 46, wherein at least one antigenic fusion protein consists of the amino acid sequence of SEQ ID NO: 4.

48.(New) The pharmaceutical composition of claim 46, wherein the heterologous carrier protein is selected from the group consisting of KLH, PhoE, rmLT, TraT, and gD from BhV-1 virus.

49.(New) An isolated antigenic peptide comprising an amino acid sequence consisting of SEQ ID NO: 4 or a fragment thereof, that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.

50.(New) An isolated antigenic fusion protein comprising an amino acid sequence of SEQ ID NO: 4 or a fragment thereof and a heterologous carrier protein that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.

51.(New) A pharmaceutical kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of claim 44 or 46.